Inhibikase Therapeutics (IKT) Other Gross PP&E Adjustments (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with $117224.0 as the latest value for Q3 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 500.36% to $117224.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $117224.0, a 500.36% increase, with the full-year FY2024 number at -$3.8 million, down 37.47% from a year prior.
- Other Gross PP&E Adjustments was $117224.0 for Q3 2025 at Inhibikase Therapeutics, up from $82306.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $117224.0 in Q3 2025 to a low of -$3.8 million in Q4 2024.
- A 5-year average of -$744502.8 and a median of -$86218.5 in 2021 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: crashed 205.82% in 2024, then surged 500.36% in 2025.
- Inhibikase Therapeutics' Other Gross PP&E Adjustments stood at -$2.3 million in 2021, then dropped by 11.14% to -$2.5 million in 2022, then decreased by 8.78% to -$2.7 million in 2023, then plummeted by 37.47% to -$3.8 million in 2024, then surged by 103.1% to $117224.0 in 2025.
- Per Business Quant, the three most recent readings for IKT's Other Gross PP&E Adjustments are $117224.0 (Q3 2025), $82306.0 (Q2 2025), and $48505.0 (Q1 2025).